INTRODUCTION
The Cholecystokinin (CCK)-2 receptor (CCK2R), formerely named CCKB/gastrin receptor is a G-protein coupled receptor which presents seven transmembrane helices and binds cholecystokin and gastrin, two structurally related neuropeptides, with a similar high affinity (Kopin et al., 1992; Wank et al., 1992) .
CCK2R is expressed in the central nervous system and in the gut where it represents the predominant CCK receptor subtype (Noble et al., 1999; Silvente-Poirot et al., 1993) . CCK2R mediates a wide spectrum of CCK-and gastrin-induced biological effects including pain perception, anxiety, gastric acid secretion, growth and differentiation of the gastric mucosa (Silvente-Poirot et al., 1993; Noble et al., 1999) .
The physiological functions mediated by CCK receptors and therefore their possible implication in associated disorders, have generated considerable interest in the identification of ligands that selectively block CCK2R activation. To date, a large panel of chemically distinct antagonists of the CCK2R have been described and used to assess functions mediated by CCK2R in animals and humans (Herranz, 2003) .
Several of these compounds have reached clinical evaluation step with indications such as anxiety and panic disorders, sleep disorders, drug dependance, pain, gastrooesephagus reflux, gastric secretion disorders (Herranz, 2003) . In spite of these major advances, one major question which recently arose with some of the nonpeptide antagonists was whether these were pure antagonists rather than partial agonists. Indeed, some reference so-called antagonists turned out to be endowed of some agonist activity in the stomach, pancreas or on transfected cells with the cDNA encoding the CCK1R or the CCK2R (Blaker et al., 2000; Blevins et al., 1994; Schmassmann et al., 1994) . Such undesired agonist activity of CCK2R ligands may represent a risk factor for human patients especially in the context of long-term use of the drugs. Indeed, aside multiple peripheral and central effects linked to its acute activation, CCK2R is endowed of oncogenic potential and/or growth promoting activity (Dufresne et al. 2005) . Further molecular investigations pointed out an interspecies genetic polymorphism regarding the CCK2R that markedly affect both affinity and activity of synthetic ligands without altering endogenous ligand induced activity (Blaker et al., 2000; Kopin et al., 1997; . These interspecies differences towards synthetic ligands were shown to be caused by sequence variations within the binding site of the CCK2R thus pointing MOL 19992 5 out the high importance of in vivo and in vitro tests with human protein targets before clinical evaluation of the molecules in humans . Availability of synthetic ligands presenting distinct pharmacological profiles together with data on the structure of the human CCK2R binding site as those recently obtained (Langer et al., 2005) , offer a unique opportunity to investigate the molecular basis for receptor activation or blocking, and to further test feasibility of "rational drug design or improvement".
Given this context, we decided to characterize pharmacological properties of several reference synthetic antagonists of the CCK2R. We used COS-7 cells as host cells for expression of the human wild-type and constitutively active CCK2R because this cell line offers the advantage to allow either high or low expression levels. Then, we docked the tested synthetic ligands into the CCK2R binding site using a procedure combining data from pharmacophore analysis on the basis of CCK2R-bound CCK conformation, flexible docking and site-directed mutagenesis data.
Results from this study show that three of the so-called antagonists of the CCK2R are in fact partial agonists, one is a neutral antagonist and two are inverse agonists on both the wild-type and the constitutively active receptor. Docking and dynamic simulation experiments provided first consistent structural explanations for the different pharmacological profiles of synthetic CCK2R ligands. In the near future, these new insights will serve to investigate the mechanism(s) whereby the human CCK2R is activated or inactivated by ligands and to optimize synthetic ligands.
MATERIALS AND METHODS
Materials. Sulfated [Thr28,Nle31]-CCK25-33 (Thr, Nle)-CCK9) was synthesized as described (Moroder et al., 1981) . 125INa (2000 Ci/mMol), and [3H]myo-inositol (5 µCi/ml) were from Pharmacia-Amersham, Les Ulis, France. Sulfated [Thr28,Nle31]-CCK25-33 was conjugated with Bolton-Hunter reagent, purified and radioiodinated as described previously (Fourmy et al., 1989) and is referred as 125I-BH-(Thr, Nle)-CCK9. The following synthetic ligands of the CCK2R (Fig. 1 -365, 260 (Lotti and Chang, 1989) (Satoh et al., 1995), 4-{[2-[[3-(lH-indol-3-yl (Revel et al., 1998),([(N-[methoxy-3 phenyl 
carbomoyl-methyl)-
3 ureido]-3-phenyl)2-propionic acid, RPR101,048 (Bertrand et al., 1994) , N-(+)-[1-(Adamant-1-ylmethyl)-2,4-dioxo-5-phenyl2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl]-N'-phenylurea, GV150,013X (Ursini et al., 2000) were supplied by Merck (West point, USA), Yamanouchi Pharmaceutical (Japan), Pfizer (Cambridge, UK), Rotta
Research laborotorium (Monza, Italy), Sanofi Aventis (Paris, France), GlaxoSmithKline (Verona, Italy), respectively.
Site-directed mutagenesis and transfection of COS-7 cells. All mutant receptor cDNAs were constructed by oligonucleotide-directed mutagenesis (Quick-ChangeTM site-directed mutagenesis kit, Stratagene, France) using the human CCK2R cDNAs cloned into pRFNeo vector as template. The presence of the desired and the absence of undesired mutations were confirmed by automated sequencing of the complete CCK2R coding sequence (Applied Biosystem). These mutants were previously characterized for their ability to bind and to respond to CCK (ArcherLahlou et al., 2005) .
COS-7 cells (1.5 x 106) were plated onto 10 cm culture dishes and grown in Dulbelcco's Modified Eagle's Medium (DMEM) containing 5% fetal calf serum in a 5% CO2 atmosphere at 37 °C. After overnight incubation, cells were transfected with 50-1000 ng/plate of pRFENeo vectors containing the cDNA for the wild-type or mutated CCK2 receptors, using a modified DEAE-dextran method. Cells were transferred to 24 well plates at a density of 10,000 to 150,000 cells/well 24 h after transfection, depending on transfected mutant and experiment to be performed. for 60 minutes at 37°C in 0.3 ml Ins-P buffer alone or with CCK in the presence of increasing concentrations of synthetic ligands. The reaction was stopped by adding 1 ml methanol/HCl to each well and the content was transferred to a column (Dowex AG 1-X8, formate form, BioRad, Hercules, CA) for the determination of Ins-P. The columns were washed twice with 3 ml distilled water and twice with 2 ml of 5 mM sodium tetraborate/60 mM sodium formate. The content of each column was eluted by addition of 2 ml of 1 M ammonium formate/100 mM formic acid. Radioactivity of 1 ml of the eluted fraction was evaluated using a liquid scintillation counter (Packard Instrument Co). EC 50 values were calculated from dose effect curves by non linear regression curve fitting using GraphPad Prism software (San Diego, USA).
Receptor binding assay.

Molecular modeling
Modeling of CCK2R.CCK-4 complex. CCK2R.CCK-4 (CCK-4: Boc-Trp-Met-AspPhe-CONH2) complex model was built on the basis of the CCK2R.CCK9 complex model previously published (Langer et al., 2005) by deleting the first five residues, adding Boc-group and refining as described.
Flexible docking of synthetic ligands. All ligands were docked into human CCK2 receptors using the docking program GOLD (Jones et al., 1997) . The receptor models were taken from the optimized complexes of human CCK2RCCK-4. The scoring function used to rank the dockings was Goldscore. GOLD default setting was , 1999) .
The distance between these elements were taken from CCK2R-bound CCK-4 so that CCK-4 was considered as a geometrical figure. The next step was the conformational search using stochastic approach (maximum conformers were 100, among them 50
were selected with maximum diversity) for other all ligands. Each conformation of each ligand was further presented again by points of potential interest and distance between them. Then, all produced geometrical figures of synthetic ligands were compared to CCK-4 figure in order to find the geometrical figure presenting the maximum of CCK-4 features and the minimum of pairwise distance tolerance value between them (the variation of this value was allowed from 0.25 to 10 by 0.25A).
Optimization. For each synthetic ligands, the position in the CCK2R was selected on the basis of best fitting between data from flexible docking, pharmacophore study and site-directed mutagenesis study. Then, the complexes were subjected to energy minimization by Steepest Descent (until convergence to 2 kcal/mol/Å) and conjugated Gradient (until convergence to 0.01 kcal/mol/Å) to remove steric clashes, using Discovery module of Insight II. During minimization C-α trace was tethered using a quadratic potential. This was performed using the Discover 3 model of InsightII module with the CFF force field. The non-bond cutoff method and the dielectric constant were set up to cell multipole and distance dependent, respectively (e=r).
Then, the complexes were futher subjected to molecular dynamics in three-step MOL 19992 9 procedure. In the first step the complex was heated from 10K up to 500K during 5000 fs, in the second step it was cooled up to 300K during 5000 fs and kept at 300K until equilibration in the third. The tethering force on C-α trace was maintained during heating and cooling periods and was successively decreased by reducing the force constant value of the quadratic potential from 100 to 80, 50, 30, 10, and 0 every 1000 ps in the third step. The integration time step was set up to 1 fs, and the calculations were performed at constant volume and temperature. A snapshot of the system was saved every 100 fs. Once the system was equilibrated, the coordinates of 20 snapshots were averaged and submitted again to the mentioned minimization procedure with no C-α restraints. In the case of refinement based on results with CCK2R having mutated Asn351, a constrain was applied between Asn353 side-chain and the closest atoms in non-peptide ligand capable to form hydrogen bond during 2000 fs and then the system was again unconstrained until equilibration.
RESULTS
Binding properties of non-peptide ligands to the human wild-type-and E151A -CCK2R
We first determined binding affinities of synthetic ligands for the human wildtype and constitutively active CCK2R. As illustrated only with the wild-type CCK2R, all tested ligands dose-dependently and fully inhibited 125-I-BH-(Thr, Nle)-CCK-9
( 
Effects of non-peptide ligands on CCK-induced stimulation of inositol phosphates by the wild-type and E151A-CCK2R
The ability of the different synthetic ligands to decrease CCK-stimulated Ins-P accumulation was assessed on COS-7 cells expressing the wild-type or the constitutively active human CCK2R ( Fig.3a-d ). Given the number of molecules to be tested, a single concentration of CCK was used for stimulation, namely 0.5 nM which corresponds to concentrations eliciting half-maximal responses (EC 50 ). Three compounds, YM022, RPR101,048 and GV150,013X inhibited CCK-stimulated production of Ins-P by the wild-type CCK2R to a level which was either close or below the basal values. In contrast, L365,260 and CR2945 only partially inhibited CCK effect whereas PD135,158 did not cause any change in Ins-P accumulation.
The inhibitory effect of YM022, RPR101,048 and GV150,013X was confirmed on CCK-stimulation of E151A-CCK2R (Fig. 3c,d ). In contrast, with this mutant, CR2945, L365,260, PD135,158 slightly increased Ins-P production obtained with 0.5 nM CCK.
Effects of non-peptide ligands on basal activities of the wild-type and E151A-CCK2R on inositol phosphate production
Results showing that three of the tested ligands, L365,260, CR2945 and PD135,158 at a concentration up to 100-fold their Ki values did not fully reverse CCK stimulation suggested that these compounds were endowed of intrinsic agonist activity. We therefore tested all molecules at increasing concentrations on both non YM022 maintained the level of Ins-P to the basal value of the cells expressing the CCK2R. In contrast, RPR101,048 and GV150,013X decreased production of Ins-P to a level that tended to that of non-transfected cells. On cells expressing constitutively active E151A-CCK2R which showed a basal level of Ins-P content reaching 2.5-fold that of the cells expressing the WT-CCK2R, PD135,158, L365,260 and CR2945 displayed stimulatory effects (Fig. 4c, d ). YM022 did not change the basal activity and, RPR101,048 and GV150,013X inhibited it by 61-64%. Thus, according to the current experimental data, PD135,158, L365,260 and CR2945 are partial agonists, with the following order of potency PD135,158 > L365,260 > CR2945, YM022 is a neutral antagonist, while RPR101,048 and GV150,013 are inverse agonists.
Dependance of basal and maximal inositol phosphate stimulations on CCK2R expression levels in COS-7 cells
To determine whether activity of non-peptide ligands of the CCK2R were dependent or not on the expression level of the WT-and E151-CCK2R by COS-7 cells, we investigated effects of these ligands on cells transfected with various amounts of plasmid encoding the receptor. Results are illustrated on Fig. 5a, b for some of the molecules tested. They show that for transfected amounts of plasmids (from 50 ng to 1000 ng) yielding expression levels of WT-CCK2R or E151A-CCK2R from 1.5 to 8.0 pmol/10 6 cells, basal activity of both WT-CCK2R and E151A-CCK2R
was dependant on receptor expression and was significantly more elevated than in non-transfected cells (p<0.001). Moreover, pharmacological behavior of each synthetic ligand was maintained at the three levels of receptor expression.
Effect of CCK2R mutation on affinity of non-peptide ligands
The effect of mutation of four reference amino acids (Blaker et al., 1998; Gales et al., 2003a; Langer et al., 2005) 
Docking of non-peptide ligands into the binding pocket of the modeled CCK2R
For flexible docking of synthetic ligands, CCK2R.CCK-4 complex was built using CCK2R.CCK9 complex previously modeled and validated on the basis of sitedirected mutagenesis data (Gales et al., 2003a; Langer et al., 2005) . By doing so, a number of distinct positions with similar scoring functions were generated (not shown). To choose between the different possibilities, pharmacophore analysis was performed using CCK2R-bound CCK-4 structure as reference. As shown on CR2945 formed hydrogen bonds with Arg356 carbonyl group, Tyr189 hydroxyl, Ser131 and Gly135 NH-backbone. In the case of L365,260, there was only one close contact between the carbonyl group of the benzodiazepin core and Asn353
(TM VI) while YM022 interacted with both Asn353 (TM VI) and with Arg356 sidechains through carbonyl group and NH-group of the amide bond. In the complex with GV150013, two carbonyl groups of the ligand interacted with Arg356, Asn353 and Ser131 side-chains, whereas RPR101,048 had a carboxyl group in strong interaction with Asn353, Arg356 and Tyr189.
Molecular dynamic simulation study of the effects of ligand binding to CCK2R
Previous studies, including ours, provided evidence that proximity of Phe sidechain of CCK with the aromatic network of CCK2R binding site composed of amino acids Tyr189 (TM IV), Tyr192 (TM IV), Phe227 (TM V), Phe342 (TM VI), Trp346 (TM VI) and Tyr350 (TM VI) was a key feature for CCK2R activation (Blaker et al., 1998; MOL 19992 13 Jagerschmidt et al., 1998; Langer et al., 2005; Pommier et al., 2003) . Analysis of the different complexes after docking and dynamic simulation procedure (Fig. 7) shows that the aromatic moiety of each ligand which, in the pharmacophore analysis, mimicked Phe of CCK-4, reached different positions with respect to the aromatic network of the CCK2R (Fig. 7) . Indeed, in complexes with PD135,158, L365,260 or CR2945, the phenyl or naphtyl rings partially overlapped Phe of CCK whereas in YM022, the phenyl ring layed in an upper site close to Tyr192 side-chain. It is worthy to note that L365260 and YM022 have the same 1,4-benzodiazepine scaffold but reached different sites in the CCK2R binding pocket. This is obviously due to the presence of the bulky substituent on 1N benzodiazepin core in YM022 which is in close contact with Val349 (TM VI) and Leu375 (TM VII) (not illustrated). Indeed, the position of YM022 is maintained upper that of L365260 ( L365,260, PD135,158 and CR2945 to this last CCK2R structure (taken from the CCK2R. RPR101,048 complex), which can be considered as "non-active state", followed by dynamic simulation, restored the aromatic network closer to that in CCK2R.CCK-4 complex. On the other hand, insertion of YM022 did not affect the aromatic network (Table 2 , Fig. 8 ).
Discussion
The aim of the current study was to precisely define pharmacological features of a series of references so-called non-peptide antagonists of the CCK2R by analyzing their activity either on basal and CCK-stimulated Ins-P production by COS-7 cells expressing the human wild-type or a constitutively active CCK2R.
Furthermore, we aimed at relating pharmacological activity of the tested ligands with their precise site of binding on the CCK2R using state-of-art methods of molecular modeling.
Apart from these above objectives, this study is the first to clearly demonstrate that the human wild-type CCK2R present a significant constitutive (ligandindependent) activity. Indeed, transient transfection of COS-7 cells with a plasmid containing cDNA encoding the CCK2R led to an increase of Ins-P production relative to cells expressing the plasmid lacking CCK2R sequence. Hence, the human CCK2R joins the group of GPCR, the native form of which exhibits a constitutive activity. In fact, spontaneous activity of native GPCRs has long been known (Cerione et al., 1984; Costa and Herz, 1989) . Since the earliest examples, a number of native GPCRs with constitutive activity have been identified (Seifert and Wenzel-Seifert, 2002 ). However, spontaneous activity of the wild-type CCK2R remained less robust than that of E151A-CCK2R mutant which exhibited a 2.5-fold higher activity than the wild-type CCK2R and near 20% of the maximal response achieved upon CCK stimulation. The first described constitutive activation of a G protein-coupled receptor generated by mutation was achieved with the 1-adrenergic receptor (Cotecchia et al., 1990) . Concerning the human CCK2R, several point mutations within the third intracellular loop and transmembrane helices, which caused constitutive activity, have been described Beinborn et al., 2004 ). In the current study, the use of E151A-CCK2R mutant to test intrinsic activity of synthetic ligands allowed easy and accurate detection of inverse agonists, namely antagonists capable of blocking ligand-independent activity of CCK2R and to distinguish them from partial agonists and neutral antagonists. In this respect, our results unambiguously demonstrated that RPR101,048 and GV150,013 are inverse agonists while YM022 is a neutral antagonist. On the other hand, tests with both wild-type and E151A-CCK2R indicated that PD135,158, L365,260 and CR2945 are partial agonists.
Concerning binding properties of the tested ligands, competition binding experiments using labeled CCK only allowed us to compare apparent affinity of the non-peptide ligands for the active states of the wild-type and E151A-CCK2R. They showed that each non-peptide ligand bound to both receptors with very close affinities. This result supports the view that conformation of the binding site of the active state of the wild-type CCK2R resembles that of E151A-CCK2R. Due to unavailability of labeled antagonist of the CCK2R, we did not measure affinity of the non-peptide ligands for the inactive state of the CCK2R, and therefore could not provide any data which would establish a relationship between activity of these compounds and their affinity for each receptor state.
Since their initial synthesis, there have been a number of reports regarding pharmacological features of CCK2R non-peptides ligands. YM022 has been used in several cell or animal models to block CCK2R-related biological effects. This compound was generally found as very efficient to reverse CCK-and gastrin-elicited biological activities ( Herranz et al. 2003) . Furthermore, in contrast to our findings, YM022 has been recently found to exhibit an inverse agonist activity on constitutive and Src-dependent internalization of a splice variant of the CCK2R (Chao et al., 2005) . On the other hand, this compound was classified as a neutral antagonist on the basis of absence of inhibition of the basal Ins-P production induced by two distinct engineered CCK2R mutants Beinborn et al., 2004) .
Among the two inverse agonists, RPR101,048 and GV150,013, only RPR101,048
was previously found by us to reverse constitutive activity of E151A-CCK2R in NIH 3T3 cells. Interestingly, RPR101048 was not only able to inhibit ligand-independent production of Ins-P but also to reverse transforming activity of the mutated E151A-CCK2R on the cells (Gales et al., 2003b) . Among the three other ligands which must be classified as partial agonists, L365,260 has been long considered as a reference antagonist of the CCK2R since, when used at adequate doses or concentrations, it reversed CCK-or gastrin-induced biological activities (Herranz, 2003) . Here, we confirmed that, in spite of its intrinsic activity, L365,260 also efficiently reversed Ins-P production elicited by 0.5 nM CCK. Our results showing that L365,260 possesses an intrinsic agonist activity is in accordance with data from several studies Blaker et al., 1998; Kopin et al., 2003) . New generations of CCK2R ligands that we could not test yet, were synthesized on the basis of L365,260 structure (Herranz, 2003) . Several of them were reported as true antagonists and even, for one of them (L740,093-R), as an inverse agonist on a constitutively active human CCK2R mutant . Concerning the peptoïd PD135,158, despite initial studies demonstrating its anxiolytic activity, this compound was further showed to stimulate second messengers formation in cells transiently expressing the human, mouse or the dog CCK2R (Hughes et al., 1990; Kopin et al., 1997; Kopin et al., 2000) . Moreover, PD135,158 was found to stimulate rat pancreatic acinar cell secretion through the CCK1R (Hocker et al., 1993) . In the family of peptoïd CCK2R ligands, several molecules were released subsequently to PD135,158 (Herranz, 2003) . It would be interesting to evaluate them using our sensitive tests with the human target (Blaker et al., 2000; Schmassmann et al., 1994) . Finally, this is the first and only study showing weak intrinsic agonist activity of CR2945.
L365,260, YM022 and GV150013 belongs to the same family of non-peptide ligands having a common 1,4-benzodiazepin core but with different substituents on 1N benzodiazepin core (Fig. 1) . These ligands which exhibit a wide spectrum of activity, namely partial agonism, neutral antagonism and inverse agonism, respectively, join the group of non-peptide ligands of GPCR in which very subtle modifications in the structure have been shown to induce dramatic changes in the intrinsic activity (Soudijn et al., 2005) . Our current findings complete previous observations with this series of benzodiazepin ligands, in particular those showing that more pronounced structural modifications such as change of C3-stereochemistry can give rise to compounds having opposite activities. This phenomenon was illustrated for enantiomers of L740093 which are partial agonist (S-enantiomer) or inverse agonist (R-enantiomer), respectively, and was further generalized to a larger series of bendodiazepin-related compounds (Kopin et al., 2003 ).
An important part of the current study addressed the challenged issue of the molecular basis for partial agonism, neutral antagonism and inverse agonism at the CCK2R. For this purpose, we carried out in silico docking of non-peptides ligands into the modeled CCK2R binding site using a procedure combining data from flexible docking, pharmacophore analysis on the basis of CCK2R-bound CCK conformation, and site-directed mutagenesis information. Then, we submitted each obtained complex to a procedure of molecular dynamic simulations in order to account for the pharmacological features of the ligand. The rational for this study was based on the facts that 1) relative positioning of the ligands in the binding pocket is determined by the structure of these ligands and their ability to interact with chemical partners within the CCK2R binding pocket; 2) the differences in ligand positioning achieved by docking and dynamic simulations can be translated in silico into changes in the sidechain orientation of aromatic residues 3) changes in side-chain orientation of aromatic residues represent a "local sensor" of the overall conformational changes which occur following binding of agonist, neutral antagonist or inverse agonist to the native CCK2R.
As we previously documented with the CCK1R, automated docking of small ligands, such as those tested here is a hazardous taste because of their "chemical symmetry" which produced similar scoring functions of the binding energy (MartinMartinez et al., 2005) . Indeed, for most of the non-peptide ligands tested, several plausible positions were generated by in silico docking in the modeled CCK2R binding site. To overcome the difficulty, we introduced data from pharmacophore analysis using a method which is distinguishable from others, by the fact that distances between key chemical elements important for activity and efficacy of the ligands were generated based on 3-D structure of the C-terminal end of CCK (CCK-4), taken from validated CCK2R.CCK complex (Langer et al., 2005) . This procedure of ligand alignment to CCK-4 structure completed data from automated docking, allowing us to determine with more confidence the orientation of the different nonpeptide ligands within the CCK2R binding site.
Previously, an attempt to build a common pharmacophore for several CCK2R ligands has been carried out using the active analog approach on the basis of eight peptidoïd derivatives (Ursini et al., 2000) . The superimposition of a GV analog to these peptidoïd structures indicated that the phenyl ring of benzodiazepine moiety and the ureidic substituent were superimposed to Phe and Trp of CCK, respectively, whereas in our work the opposite situation was obtained (Fig. 6 ). Another pharmacophore study was recently applied to a set of 33 antagonists of CCK receptors comprising 6 classes of structurally distinct compounds. In this later work, the conformational search was carried out for all compounds leading to conformational models which were used for the generation of pharmacophore models. The authors selected the best one which has two hydrogen bond donors, one aliphatic and one aromatic moieties (Chopra et al., 2005) what differs from our finding. At last, it is worthy to mention that earlier studies of gastrin fragments in the absence of the structural receptor information showed that CCK-4 could exist in a 3 10 helix with two aromatic rings of Trp and Phe interacting in a π-stacking arrangement at a distance of 5-7Å (Kalindjian et al., 1994) , whereas in our study, the conformation of CCK-4 in its binding site is more extended since the distance between Trp and Phe is about 10-12Å. These different results highlight difficulties to draw reliable pharmacophore of non peptide ligands of the CCK2R independently of information regarding the structure of bound ligands.
Another lesson learnt from our study of non-peptide docking in the CCK2R binding site is related to the difficulty encountered to define acceptor/donor elements in non-peptide ligands and surrounding residues of the CCK2R binding site such as
Asn353. In fact, results from site-directed mutagenesis study and molecular modeling indicated that in the CCK2R.CCK complex, Asn353 (TM VI) interacted as an acceptor with NH group of the CCK C-terminal amide (Langer et al., 2005) . Site-directed mutagenesis results from the current study supported that L365,260, PD135,158, YM022, GV150,013 and RPR101,048 but not CR2945 were likely in interaction with Interestingly, in accordance with these results, previous study about identification of the binding site of pyridopyrimidine antagonists on the human CCK1R using a different strategy involved Asn333 (corresponding residues to Asn353 of CCK2R) and this residue was found to play a donor role (Martin-Martinez et al., 2005) .
Pharmacophore studies with non-peptide ligands also revealed that all compounds have in their structure a part that will mimic Phe side-chain of CCK once bound to the CCK2R. However, refined docking of these ligands followed by dynamic simulation generated significant variations in the location of phe mimetic relative to the aromatic network of the CCK2R. This was a result of both 3-D structure of the and are mean ± S.E. of three to six separate experiments performed in duplicate. The value "0" correspond to Ins-P level in non -tansfected COS-7 cells and the value "1" corresponds to basal inositol phosphate level in COS-7 cells expressing the wild-type or the mutated CCK2R. 
